Petros named interim director of Cancer Center

William P. Petros, PharmD, has been named interim director of the Mary Babb Randolph Cancer Center at WVU, according to Clay Marsh, MD, vice president and executive dean for health sciences.

He assumes the leadership role formerly held by Scot Remick, MD, whose eight-year term as Cancer Center director saw the institution grow in physical size, serve hundreds more patients each year and take a leading position in cancer research.

“I want to thank Scot for his service to WVU, the Cancer Center and the state of West Virginia,” said Dr. Marsh. “He has done an admirable job of building a strong cancer center, an effective leadership team and a statewide network of cancer clinicians who not only provide excellent care but advance clinical research in many West Virginia communities.”

Petros, a member of the WVU faculty since 2001, holds the Mylan Chair of Pharmacology in the WVU School of Medicine and is also on the faculty of the School of Pharmacy. He has served the Cancer Center as associate director for anti-cancer drug development since his arrival at WVU.

He is an experienced cancer researcher who has served on a number of NIH review committees and other national research organizations. He is a graduate of the WVU School of Pharmacy and earned his doctoral degree at the Philadelphia College of Pharmacy and Science, then completed research training at St. Jude Children’s Research Hospital.

“Bill Petros will join our clinical leadership team – Hannah Hazard, MD, Michael Craig, MD, and Geraldine Jacobson, MD – in taking the Cancer Center forward on the strong foundation that Dr. Remick has built,” Marsh said. “I am very excited about the future of the Mary Babb Randolph Cancer Center and what it can accomplish for the people of West Virginia, as well as for the broader field of basic cancer research.”

Visit Inside View for the full article.